Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Months
Portfolio Pulse from Vandana Singh
Avrobio Inc (NASDAQ:AVRO) announced positive follow-up data from a Phase 1/2 trial of its investigational gene therapy, AVR-RD-04, for cystinosis. The treatment demonstrated durability across key measures up to 36 months, with no adverse events related to the drug product. The company plans to initiate late-stage cystinosis trial activities in 2H 2023.
May 18, 2023 | 4:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avrobio's positive follow-up data from its Phase 1/2 trial of gene therapy for cystinosis demonstrates treatment durability and no adverse events, potentially boosting investor confidence.
The positive follow-up data from Avrobio's Phase 1/2 trial of its investigational gene therapy for cystinosis demonstrates treatment durability up to 36 months and no adverse events related to the drug product. This news is likely to boost investor confidence in the company's ability to develop effective treatments and may lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100